secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-07-12T23:59:59+00:00
Accession:  0001104659-23-080168
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics starts randomized Part B of DKN-01 Phase 2 CRC study after positive Part A
--------------------------------------------------------------------------------

- Initiated 130-patient randomized controlled Part B of DeFianCe study of DKN-01 in second-line advanced colorectal cancer.
- Part A enrolled 33 aggressive CRC patients and exceeded 20% overall response rate, triggering Part B.
- Primary endpoint of Part B is progression-free survival; enrollment expected ~12 months, data late 2024.
- Regained Nasdaq compliance with minimum bid price rule after 11 consecutive days above $1.00 (July 6, 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923080168/0001104659-23-080168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923080168/tm2321081d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer